Selected research
Industry Growth & Trends
Global Antisense Oligonucleotide Therapies Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Antisense Oligonucleotide Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Antisense Oligonucleotide Therapies market include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Antisense Oligonucleotide Therapies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antisense Oligonucleotide Therapies market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antisense Oligonucleotide Therapies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antisense Oligonucleotide Therapies.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Antisense Oligonucleotide Therapies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antisense Oligonucleotide Therapies Market by Company
Sarepta Therapeutics
Nippon Shinyaku
Ionis Pharmaceuticals
Antisense Oligonucleotide Therapies Segment by Type
Without GalNAc-conjugated
With GalNAc-conjugated
Antisense Oligonucleotide Therapies Segment by Application
Cancer
Cardiovascular Diseases
Genetic Disease
Other
Antisense Oligonucleotide Therapies Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Antisense Oligonucleotide Therapies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Without GalNAc-conjugated
- With GalNAc-conjugated
Applications
- Cancer
- Cardiovascular Diseases
- Genetic Disease
- Other
Companies covered
- Sarepta Therapeutics
- Nippon Shinyaku
- Ionis Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Antisense Oligonucleotide Therapies Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Antisense Oligonucleotide Therapies Market Size by Region (2021-2032)
- 1.4.1 Global Antisense Oligonucleotide Therapies Market Size by Region (2021-2026)
- 1.4.2 Global Antisense Oligonucleotide Therapies Market Size by Region (2027-2032)
- 1.5 Key Regions Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 1.5.1 North America Antisense Oligonucleotide Therapies Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Antisense Oligonucleotide Therapies Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size Growth Rate (2021-2032)
- 1.5.4 South America Antisense Oligonucleotide Therapies Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Antisense Oligonucleotide Therapies Market Size Growth Rate (2021-2032)
2 Antisense Oligonucleotide Therapies Market by Type
- 2.1 Type Introduction
- 2.1.1 Without GalNAc-conjugated
- 2.1.2 With GalNAc-conjugated
- 2.2 Global Antisense Oligonucleotide Therapies Market Size by Type
- 2.2.1 Global Antisense Oligonucleotide Therapies Market Size Overview by Type (2021-2032)
- 2.2.2 Global Antisense Oligonucleotide Therapies Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Antisense Oligonucleotide Therapies Market Size Forecasted by Type (2027-2032)
- 2.3 Global Antisense Oligonucleotide Therapies Market Size by Regions
- 2.3.1 North America Antisense Oligonucleotide Therapies Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Antisense Oligonucleotide Therapies Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Antisense Oligonucleotide Therapies Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Antisense Oligonucleotide Therapies Market Size Breakdown by Type (2021-2026)
3 Antisense Oligonucleotide Therapies Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Cardiovascular Diseases
- 3.1.3 Genetic Disease
- 3.1.4 Other
- 3.2 Global Antisense Oligonucleotide Therapies Market Size by Application
- 3.2.1 Global Antisense Oligonucleotide Therapies Market Size Overview by Application (2021-2032)
- 3.2.2 Global Antisense Oligonucleotide Therapies Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Antisense Oligonucleotide Therapies Market Size Forecasted by Application (2027-2032)
- 3.3 Global Antisense Oligonucleotide Therapies Market Size by Regions
- 3.3.1 North America Antisense Oligonucleotide Therapies Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Antisense Oligonucleotide Therapies Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Antisense Oligonucleotide Therapies Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Antisense Oligonucleotide Therapies Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Antisense Oligonucleotide Therapies Industry Trends
- 4.2 Antisense Oligonucleotide Therapies Industry Drivers
- 4.3 Antisense Oligonucleotide Therapies Industry Opportunities and Challenges
- 4.4 Antisense Oligonucleotide Therapies Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Antisense Oligonucleotide Therapies Revenue (2021-2026)
- 5.2 Global Antisense Oligonucleotide Therapies Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Antisense Oligonucleotide Therapies Key Company Headquarters & Area Served
- 5.4 Global Antisense Oligonucleotide Therapies Company, Product Type & Application
- 5.5 Global Antisense Oligonucleotide Therapies Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Antisense Oligonucleotide Therapies Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Antisense Oligonucleotide Therapies Players Market Share by Revenue in 2025
- 5.6.3 2025 Antisense Oligonucleotide Therapies Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sarepta Therapeutics
- 6.1.1 Sarepta Therapeutics Company Information
- 6.1.2 Sarepta Therapeutics Business Overview
- 6.1.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
- 6.1.5 Sarepta Therapeutics Recent Developments
- 6.2 Nippon Shinyaku
- 6.2.1 Nippon Shinyaku Company Information
- 6.2.2 Nippon Shinyaku Business Overview
- 6.2.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
- 6.2.5 Nippon Shinyaku Recent Developments
- 6.3 Ionis Pharmaceuticals
- 6.3.1 Ionis Pharmaceuticals Company Information
- 6.3.2 Ionis Pharmaceuticals Business Overview
- 6.3.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
- 6.3.5 Ionis Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 7.3 North America Antisense Oligonucleotide Therapies Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 8.3 Europe Antisense Oligonucleotide Therapies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 10.3 South America Antisense Oligonucleotide Therapies Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Antisense Oligonucleotide Therapies Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst